Actinium Pharmaceuticals Inc (ATNM)


Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Actinium Pharmaceuticals Inc chart...

About the Company

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o

CEO

Sandesh Seth

Exchange

NYSE MKT LLC

Website

https://www.actiniumpharma.com/

$0M

Total Revenue

56

Employees

$172M

Market Capitalization

-3.28

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ATNM News

Actinium Pharmaceuticals files patent for humanized anti-human cd45 antibody pharmaceutical compositions

12d ago, source: Pharmaceutical Technology

Discover Actinium Pharmaceuticals Inc.'s groundbreaking patent for humanized anti-human CD45 antibodies and pharmaceutical compositions. Learn about the unique antibody structures designed for ...

Buy Rating Affirmed: Strategic Advances and Clinical Potential Bolster Actinium Pharmaceuticals’ Outlook

7d ago, source:

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price ...

High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment

3d ago, source:

The post High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment appeared first on InvestorPlace.

Actinium Pharmaceuticals gets grant for treatment of acute myeloid leukemia using combination pharmaceutical therapy

13d ago, source: Pharmaceutical Technology

Discover Actinium Pharmaceuticals' innovative method for treating acute myeloid leukemia with a BCL-2 inhibitor and alpha-emitting isotope-labeled agent. Learn how this patented combination therapy ...

Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)

4d ago, source: Business Insider

Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals. Currently, the analyst consensus on ...

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

on MSN ago, source:

Aeva Technologies, Inc. AEVA shares declined 5.4% to $1.23 in pre-market trading. Aeva said it expects a 1-for-5 reverse ...

Production at API Industrial Park to begin next month

2d ago, source: The Daily Star

Production of active pharmaceutical ingredients (APIs) at the API Industrial Park in Gazaria of Munshiganj will begin next ...

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12d ago, source:

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation ...

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

13d ago, source:

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...

API sprawl: navigating the web of connectivity and security challenges

on MSN ago, source:

However, as the API ecosystem expands, so too do the challenges, in particular introducing new vulnerabilities and greater ...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10d ago, source: Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...